“Patients taking Eli Lilly & Co.’s blockbuster weight-loss shot were 94% less likely to develop diabetes in a three-year study that illuminates the long-term health benefits of treating obesity.

It’s the longest continuous study of Lilly’s drug Zepbound to date, the company said in a statement Tuesday. More than 1,000 patients with obesity and prediabetes were randomized to receive Lilly’s medicine or a placebo, and followed for just over three years.

Those on the highest 15 milligram weekly dose of Zepbound also lost roughly 23% of their body weight during the 176-week study period, showing that the popular obesity drug keeps working over the long term.”

From Bloomberg.